Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02698826 · ClinicalTrials.gov registry record · Phase 1

Reoxygenation After Cardiac Arrest II (REOX II Study)

A Phase 1 study of Cardiac Arrest, sponsored by The Cooper Health System.

Completed
Registry status
Phase 1
Development phase
16
Enrollment target
5
Study locations

NCT02698826 is a Phase 1 study of Cardiac Arrest that has completed, run by The Cooper Health System. The registered enrollment target is 16 participants, below the 1,479-participant average among 31 other Cardiac Arrest trials with a reported enrollment target (99% lower). The trial reports 5 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02698826, a Phase 1 study of Cardiac Arrest, has completed, sponsored by The Cooper Health System.

COMPLETED
Registry status
Phase 1
Development phase
16 participants
Enrollment target
5
Study locations

Study Summary

The broad objective of this study is to test the association between hyperoxia exposure after resuscitation from cardiac arrest and outcome. After obtaining written informed consent subjects enrolled in REOX II will undergo a rapid faction of inspired oxygen (FiO2) optimization protocol to prevent exposure to hyperoxia. We will compare outcomes between subjects enrolled in REOX I (observational study only) and REOX II (intervention: rapid FiO2 optimization protocol). Our overarching hypothesis is that exposure to hyperoxia after return of spontaneous circulation (ROSC) is associated with increased oxidative stress and worsened neurological and cognitive outcomes.

Conditions Studied

Cardiac Arrest

Interventions

  • OTHER Protocol for rapid FiO2 optimization

Study Locations (5)

Indiana

  • Indiana University/ Methodist Hospital - Indianapolis

Massachusetts

  • Beth Israel Deaconess Medical Center - Boston

Mississippi

  • University of Mississippi Medical Center - Jackson

New Jersey

  • Cooper University Hospital - Camden

Pennsylvania

  • Hospital of the University of Pennsylvania and Penn Presbyterian Medical Center - Philadelphia

Trial Details

FieldValue
Enrollment Target 16 participants
Start Date 2016-04
Est. Completion 2018-10
Phase Phase 1

Sponsor

The Cooper Health System

39 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02698826

The ClinicalTrials.gov registry entry for NCT02698826 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,479-participant average among 31 other Cardiac Arrest trials with a reported enrollment target (99% lower). The listed sponsor is The Cooper Health System, which has 39 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Cardiac Arrest appearing as the primary indexed condition, and to 1 intervention - of which Protocol for rapid FiO2 optimization is the first listed.

NCT02698826 reports 5 study locations spanning 5 distinct geographic areas - top geographies include Indiana, Massachusetts, Mississippi.

Frequently Asked Questions

What is clinical trial NCT02698826 about?

NCT02698826 is a clinical study titled "Reoxygenation After Cardiac Arrest II (REOX II Study)". The broad objective of this study is to test the association between hyperoxia exposure after resuscitation from cardiac arrest and outcome. After obtaining written informed consent subjects enrolled in REOX II will undergo a rapid faction of inspired oxygen (FiO2) optimization protocol to prevent e...

What is the current status of trial NCT02698826?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2016-04. Estimated completion is 2018-10.

What conditions does trial NCT02698826 study?

This clinical trial studies the following conditions: Cardiac Arrest.

What interventions are being tested in trial NCT02698826?

The interventions under investigation include: Protocol for rapid FiO2 optimization (OTHER).

Who is sponsoring clinical trial NCT02698826?

This trial is sponsored by The Cooper Health System, which has 39 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02698826 being conducted?

This trial has 5 study locations across Indiana, Massachusetts, Mississippi, New Jersey, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Cardiac Arrest

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Cardiac Arrest

All registered trials for this condition

Indiana

All trials with a study site in Indiana

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.